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ABSTRACT 
The aim of the present work was to formulation and evaluation of pH Triggered in-situ Ophthalmic Gel of Besifloxacin 
Hydrochloride to overcome the drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. 
Carbopol 934 and HPMC K100. Carbopol 934 were used as gelling agent and HPMC K100 were used as bioadhesive polymer. 
Besifloxacin Hydrochloride shows activity against a wide range of Gram-positive and negative ocular pathogens: examples are 
 Corynebacterium pseudodiphtheriticum, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus 
pneumoniae and Streptococcus salivarius. The in situ gelling system involves sol-to-gel transition in the cul-de-sac upon instillation 
to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations were evaluated 
for clarity, pH, viscosity, Bioadhesive strength of gel, gel strength gel, Drug Content, In-vitro Drug Release Study, Antibacterial 
Activity, Isotonicity Evaluation, HET-CAM Test and stability studies. The drug content was in the range of 97-99.57 %. 
Formulation F5 selected as optimized on the basis of evaluation. It shows highest drug release upto 8hrs. It shows good antibiotic 
activity against Staphylococcus aureus. The optimized formulation was isotonic with blood cells. It passes sterility test. The 
optimized formulation passes the ocular irritancy test i.e. HET-CAM Test. The formulation kept for the stability study for 3 months. 
Short term stability study indicates that room temperature 400±20 was appropriate storage condition for formulations. 
Keywords: pH Triggered, bioadhesive polymer, Carbopol 934, HPMC K100, HET-CAM Test, Antibacterial Activity. 
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INTRODUCTION 
One of the most challenging and interesting drug 
delivery is ophthalmic drug delivery for the 
pharmaceutical scientist. The anatomy, biochemistry and 
physiology of the eye render this organ delicately 
impermeable to foreign substances. To evade the 
protective barriers of the eye, the challenge to the 
formulator is to circumvent the protective barriers of the 
eye without causing permanent tissue damage. The 
development of newer, more sensitive diagnostic 
techniques and therapeutic agents render urgency to the 
development of more successful ocular delivery system
1
. 
Several new preparations have been developed for 
ophthalmic use, not only prolong the contact time of the 
vehicle at ocular surface, but also to slow down the 
elimination of the drugs. This problem can be overcome 
by using In-situ gel forming ophthalmic drug delivery 
systems, prepared from polymers that exhibit reversible 
phase transition and pseudo-plastic behavior to minimize 
interference with blinking. In situ gel forming drug 
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delivery is a type of mucoadhesive drug delivery system. 
Such system can be formulated as liquid dosage form 
suitable for administration by instillation in to the eye, 
which upon exposure to the eye, shift to the gel phase 
depends upon physiological pH condition of eye 
2,3
. pH 
sensitive polymers contain pendant acidic or basic 
groups that can either accept or release protons in 
response to changes in environmental pH. In case of 
weakly acidic group, swelling of hydrogel increases as 
the external pH increases, while decreases in case of 
weakly basic groups. Gelling of the solution is triggered 
by a change in pH
4
. In situ gelling system becomes very 
popular nowadays because of their several advantages 
over conventional drug delivery systems like sustained 
and prolonged release of drug, reduced frequency of 
administration, improved patient compliance and 
comfort
5
. In this study, In situ gelling system of 
Besifloxacin Hydrochloride were prepared using 
polymers carbopol 934 and HPMC K100. Carbopol 934 
used in concentration 0.1-0.3 % w/v and HPMC K100 
was in concentration 0.6-1% w/v. 
MATERIAL AND METHOD 
Besifloxacin Hydrochloride was obtained from Ajanta 
Pharma Ltd. Kandiwali West, Mumbai, India as a gift 
sample. Carbopol 934 and HPMC K100 were purchased 
from Research-Lab Fine Chem. Industry –Mumbai. 
Development of Besifloxacin Hydrochloride 
Ophthalmic Gel 
Composition of formulation batches as per 3
2
 factorial 
design shown in Table 1. 
         
Table 1: Composition of Formulation Batches As Per 3
2
 Factorial Design 
Formulation code 
  
Ingredients  
 
F1 
 
 
F2 
 
 
F3 
 
 
F4 
 
 
F5 
 
 
F6 
 
 
F7 
 
 
F8 
 
 
F9 
 
Besifloxacin 
Hydrochloride (w/v) 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
 
0.6 
Carbopol 934 (w/v)  
0.1 
 
0.2 
 
0.3 
 
0.1 
 
0.2 
 
0.3 
 
0.1 
 
0.2 
 
0.3 
HMMC K100 (w/v)  
0.6 
 
0.6 
 
0.6 
 
0.8 
 
0.8 
 
0.8 
 
1 
 
1 
 
1 
Disodium edentate (w/v)  
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
Benzalkonium Chloride 
(w/v) 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
0.01 
 
Purified water (ml) 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
               
Formulation of Ophthalmic in situ Gel:
 
The quantities of drug and other ingredients were 
weighed as per Table no.1 and formulations were 
prepared in following manner
 6
: 
Cleaning of glassware and container: All the 
glassware’s were washed using distilled water. After 
washing glassware’s dried at 160-165° for 1 hr in hot air 
oven for sterilization. 
Preparation of solution ‘A’: Besifloxacin 
Hydrochloride was accurately weighed (0.6 g) and then 
dissolved in pH 6.8 phosphate buffer (50ml). 
Preparation of polymer dispersion ‘B’: The Carbopol 
934 and HPMC K100 was accurately weighed and then 
dissolved in distilled water (50ml) was allowed to 
hydrate for 24 h to produce a clear solution. The 
Benzalkonium chloride and Disodium edetate was added 
to the above polymer dispersion. 
Mixing of ophthalmic formulation: The solution ‘A’ 
and solution ‘B’ was mixed with continued stirring and 
pH of formulation was maintained using 0.1N NaOH. 
Sterilization of ophthalmic formulation: Prepared 
solutions were autocla ed at      for 15 min. 
Aseptic filling to container: The formulation was 
aseptically transferred to previously sterilized glass 
bottles and sealed. 
Evaluation of in-situ ophthalmic gel of besifloxacin 
hydrochloride  
Physical parameter:
 
 
Clarity: 
 The formulations were visually checked for the clarity. 
pH:  
pH of each formulation was determined by using Digital 
pH meter (Sistronic Digital pH meter 335). This was 
previously calibrated by standard pH 4 and pH 7. The 
pH values were recorded immediately after preparation.  
Rheological study: 
Viscosity: 
The rheological properties of gels were determined by 
the Brookfield viscometer; type DV-II + PRO using 
spindle no.61& 63. At two different pH the viscosity of 
formulations was taken at pH 6.8 and pH 7.4. 
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Measurement of the gel strength: 
Measurement of the gel strength was carried out in 50 
ml graduated cylinder. 25ml of sample was put in 
graduated cylinder. On the surface of gel a weight of 
14.33g was placed. The gel strength was determined by 
the time in second required to penetrate the weight 5 cm 
into the gel at physiological temperature
12
. All 
measurements were performed in triplicate (n=3).      
Bioadhesive Strength
 
“Detachment Stress is the force required to detach the 
two surfaces of mucosa when a formulation/gel is placed 
in between them”. The detachment stress was measured 
by using a modified analytical balance (A). A fresh goat 
membrane was obtained from local slaughter house
7
. A 
section of fresh mucosa was cut from the goat eye and 
washed with saline solution. 
Fabrication of equipment:  
The equipment was fabricated by us in the laboratory as 
shown in figure 1. A double beam physical balance was 
taken, both the pans were removed. The left pan was 
replaced with a brass wire, to which was hanged a teflon 
disc (D), also locally fabricated. The dimensions are 2 
cm height and include an expanded cap of diameter 3.8 
cm and thickness 2 cm. Another teflon disc of 2 cm 
height and 1.5 cm diameter was placed right below the 
suspended disc upon the base of the balance. The right 
pan (B) was replaced with a lighter pan so that, the left 
pan weighs 5.25 gm more than the right pan. The lower 
Teflon block was intended to hold the mucosal tissue (E) 
of goat corneal membrane and to be placed in a beaker 
containing simulated tear fluid pH 7.4
7
.   
Measurement of adhesion force:   
Goat corneal membrane was obtained commercially; the 
cornea was collected into a sterile container containing 
sterile buffer solution of pH 7.4. The corneal membrane 
brought was stored in a refrigerator until use. 
The following procedure was used for all the test 
formulations using the above equipment. The goat 
corneal membrane was removed from refrigerator and 
allowed to attain equilibrium with ambient conditions in 
the laboratory. The goat corneal membrane was 
carefully excised, without removing connective and 
adipose tissue and washed with simulated tear fluid 
solution. The tissue was stored in fresh simulated tear 
fluid solution. Immediately afterwards the membrane 
was placed over the surface of lower teflon cylinder (E) 
and secured. This assembly was placed into beaker 
containing simulated nasal solution pH 7.4 at 37 ± 
2°.From each batch, some quantity of gel was taken and 
applied on the lower surface of the upper teflon cylinder. 
The beaker containing mucosal tissue secured upon 
lower cylinder (E), was manipulated over the base of the 
balance so that, the mucosal tissue is exactly below the 
upper cylinder (D). The exposed part of the gel was 
wetted with a drop of simulated tear fluid solution, and 
then a weight of 10 gm was placed above the expanded 
cap, left for 10 minutes. After which the gel binds with 
mucin. The weight was removed. Then slowly and 
gradually weights were added on the right side pan till 
the gel separates from the mucosal surface/ membrane. 
The weight required for complete detachment is noted 
(W1) (W1-5.25G)) gives force required for detachment 
expressed in weight in grams. Procedure was repeated 
for two more times. Average was computed and 
recorded.   
 
Figure 1: Modified Bioadhesion apparatus 
           A: Modified balance, B: Weighing pan, C: Weight                      
           D: Upper taflon disc, E: Lower taflon disc                                 
           F: Corneal membrane G: Simulated tear fluid. 
Calibration of test equipment:    
Initially, a gel from the same batch was taken ten times 
and individual force required for complete detachment 
was noted and SD was calculated.   
Force of adhesion (N): 
                      
                     
    
× 9.81 
                       
                             
                         
 
Drug Content
 
For determination of drug content 1ml of formulation 
was taken and diluted with 100ml of phosphate buffer. 
Out of 100ml 5ml was withdrawn and again diluted with 
25 ml of phosphate buffer
8
. The concentration of 
Besifloxacin Hydrochloride was determined by using 
UV Visible Spectrophotometer at 289nm. 
In-vitro Drug Release Study
 
The laboratory designed diffusion cell was shown in 
figure 2. With the help of diffusion cell through egg 
membrane as a biological membrane the in-vitro drug 
release study of the formulation was carried out. 
Diffusion cell with inner diameter 1.4cm was used for 
the study. The formulation 1 ml were placed in donor 
compartment and in the receptor compartment freshly 
prepared 100 ml artificial tear fluid solution (sodium 
chloride 0.670g, sodium bicarbonate 0.200g, potassium 
chloride 0.248 g, calcium chloride dehydrated 0.008g, 
distilled water q.s. 100ml) was placed. Egg membranes 
were mounted in between donor and receptor 
compartment. The position of the donor compartment 
was adjusted so that egg membrane just touches the 
diffusion medium. The whole assembly was placed on 
the thermostatically controlled magnetic stirrer
12
. The 
temperature of the medium was maintained at 37° ± 
0.5°. 2ml of sample is withdrawn from receiver 
compartment after 30 min, 1, 2, 3, 4, 5, 6, 7 & 8 hrs and 
same volume of withdrawn was replaced by fresh 
medium. The withdrawn samples was diluted to 10ml in 
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a volumetric flask with fresh artificial tear fluid and 
analyzed by UV spectrophotometer at 289 nm. 
 
Figure 2: Laboratory designed diffusion cell. 
A- Test tube containing formulation. B- Egg membrane.   
C- beaker containing simulated tear fluid solution.  
D- Magnetic stirrer. 
Antibacterial Activity
 
The determination of antibacterial activity of 
formulations was carried out by using an agar medium. 
Standard petri dishes (9cm diameter) containing medium 
to a depth of 0.5cm were used for the study. The sterility 
of the lots was controlled before use. Suspension was 
prepared by suspending 1-2 colonies of Staphylococcus 
aureus (MH1714) from 24hr cultures in nutrient agar 
medium into tubes containing 10 ml of sterile saline. 
The tubes were diluted with saline. The inoculum 
(0.5mL) was s read o er the surface of agar and the 
 lates were dried at     for 15 min prior to placing the 
formulation. The bores of 0.5cm diameter were prepared 
and 2 drops of formulation (0.6%w/v) were added in the 
bores. After incubation at     for 24hrs, the zone of 
inhibition around the bores was measured
9,10,11,12
. 
Isotonicity Evaluation
 
For the study of isotonicity formulations were mixed 
with few drops of diluted blood on a slide. The diluted 
blood was  re ared by using Grower’s solution and 
Slide was observed under microscope at 45x 
magnification
12,13
. The shape of blood cells were 
compared with standard marketed ophthalmic 
formulation. 
Test for sterility  
The sterility test was carried out according to IP (2014). 
The method direct inoculation was used for sterility test. 
5 ml of sterile fluid thioglycolate medium, artificial fluid 
thioglycolate and Soyabean casein digest medium were 
used. The three set were prepared each set containing 
three tubes of each medium. The first set, negative 
control was sterile media. The second set, positive 
control was the sterilized media incubated with 
staphylococcus aureus. And the third set was test set. 
The 1mL sterile optimized formulation was taken and 
this formulation was diluted with 100mL sterile water 
for injection, from this 5mL test solution were added in 
each medium. The incubation time was 14 days for 
detection of bacterial and fungal contamination at 20-25 
 . The visual inspection of turbidity was used as method 
of detection
12,14,15
.  
HET-CAM Test 
The Hen’s Egg Test on the Chorioallantoic membrane 
(HET-CAM) is another alternative method to animal 
experimentation for assaying corrosives or sever ocular 
irritations, using Chorioallantoic membrane of 
embryonated hen’s egg. This test assesses the damage to 
this membrane to determine the potential irritatation to 
the conjunctiva. Its well developed vascularization 
provides an ideal model for studies of ocular 
irritation
16,17
.   
9 Days fertilized hen’s eggs 
 
The CAM (25%) is treated with the test item for 30 sec. 
 
Test item was wash off 
 
Effect assessed within 5 min. 
End Point:  Redness, Irritation 
Stability studies
 
For the stability study the formulation was taken for 3 
months. The test condition for stability study was 
temperature condition was at room temperature (40
0 
± 
2
0
) a Relative humidity was 75± 5%. The formulations 
were evaluated mainly for their physical characteristics 
at the predetermined intervals of 30 days like 
appearance, clarity, pH, viscosity and drug content
18,19
. 
RESULT AND DISCUSSION  
Physical parameter 
 Clarity 
On careful visual inspection against dark and white 
background, all the prepared ophthalmic gel 
formulations were found to be free from any suspended 
particulate matter. All the formulations were found to be 
clear. The prepared formulations are as shown in Figure 
3.
 
 
Figure 3: Prepared Formulation Batches 
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pH 
The pH values of formulations were shown in Table 2. 
The pH of all the formulations from F1 to F9 was found 
to be in the range of 6.67 to 6.84. Ideally, the 
ophthalmic solutions should passes pH in the range of 
6.5-8.5, so as to minimize discomfort or excessive tear 
flux causing faster drainage of the instilled dose due to 
corneal irritation. 
Rheological study 
Viscosity 
The Viscosity profile of formulations at pH 6.8 and pH 
7.4 is shown in Figure 4 and 5 respectively. 
Viscosity v/s rpm plots for all formulations shows 
decrease in viscosity as shear rate (rpm) was increased 
which indicate that gel has the pseudo plastic flow. As 
pH was increased the increase in viscosity was 
observed. Concentration of Carbopol 934 and HPMC K-
100 was a major factor affecting viscosity of 
formulations. In combination with Carbopol 934 and 
HPMC K-100 was shown considerable increase in 
viscosity when concentration of Carbopol 934 is 0.3% 
w/v & HPMC K-100 is 1% w/v. 
Table 2: pH Values Of Formulations 
S. N. Formulation code Observed pH 
(±S.D.) 
1 F1 6.82 ± 0.001 
2 F2 6.84 ± 0.001 
3 F3 6.78 ± 0.002 
4 F4 6.69± 0.004 
5 F5 6.80± 0.001 
6 F6 6.86 ± 0.001 
7 F7 6.81 ± 0.01 
8 F8 6.79 ± 0.004 
9 F9 6.67 ± 0.001 
 
 
 
Figure 4: Viscosity profile of formulations at pH 6.8 
 
Figure 5: Viscosity profile of formulations at pH7. 
 
Measurement of the Gel Strength 
The gel strength of ophthalmic formulations is shown in 
Table 3. 
The gel strength was found to be affected by 
concentrations of gelling agent, Bioadhesive polymers 
and also by the pH. Optimal bioadhesive gel must have 
suitable gel strength so as to be administered easily and 
can be retained Ocular region without leakage after 
administration. Gel strength of all formulations showed 
comparable results as that of viscosity results. 
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Table 3: Gel Strength of Formulations 
S. N. Formulation code Gel strength (sec) ±S.D.) 
1 F1 0.58±0.005 
2 F2 0.61 ± 0.01 
3 F3 0.84 ±0.07 
4 F4 1.05 ± 0.05 
5 F5 1.30 ± 0.08 
6 F6 1.50 ± 0.43 
7 F7 1.50 ± 0.41 
8 F8 2.26 ± 0.12 
9 F9 2.40 ± 0.04 
 
Bioadhesive strength 
The detachment stress of formulation is shown in Table 
4. 
Bioadhesive force means the force with which gels bind 
to ocular mucosa. Greater bioadhesion is indicative of 
prolonged residence time of a gel and thus prevents its 
drainage from cul-de-sac. The bioadhesion force 
increased significantly as the concentration of 
bioadhesion polymers increased. The Detachment Stress 
was determined for ophthalmic gels. Results of this test 
indicate that the variable Carbopol 964 and HPMC K100 
both are having effect on bioadhesive strength. It shows 
that bioadhesive force was increased with the increasing 
concentration of the Carbopol 964 and HPMC K100. 
Drug content 
The percent drug content of ophthalmic gel formulations 
was shown in Table 5. 
The percentage drug content of all prepared ophthalmic 
formulations was found to be in the range of 97-99.57 
%. Therefore uniformity of content was maintained in all 
formulation. 
Table 4: Bioadhesive Strength of Formulations 
Formulation code Detachment Force (N) (±S.D) 
F1 0.1898 ± 0.035 
F2 0.2019±0.027 
F3 0.2424 ±0.0005 
F4 0.3507 ± 0.005 
F5 0.4393 ± 0.005 
F6 0.4869± 0.005 
F7 0.5077± 0.005 
F8 0.6407 ± 0.005 
F9 0.6457± 0.0005 
 
In-vitro drug release study 
Out of nine formulations maximum release after 8 hrs 
was found for F5 formulation. This indicates release of 
99.1 % drug availability. 
In-vitro drug release profile of formulations was shown 
in Figure 6. 
Table 5: Percent Drug Content of Ophthalmic Gel 
Formulation  Code Drug content (%) (±S.D.) 
F1 98.86± 0.12 
F2 98.54± 0.17 
F3 98.54±0.16 
F4 98.97± 0.065 
F5 99.57± 0.172 
F6 97.67± 0.113 
F7 98.97± 0.13 
F8 98.34± 0.17 
F9 97.58± 0.12 
 
 
Figure 6: In-vitro drug release profile of formulations 
Antibacterial activity  
The standard value of Besifloxacin Hydrochloride 
against Staphylococcus aureus for maximum zone of 
inhibition is 30 mm. The study indicates that 
Besifloxacine Hydrochloride retained its antibacterial of 
efficiency when formulated as an ophthalmic in-situ gel 
and drug was active against selected strains of micro-
organism. F5 formulation showed - 27.12 mm zone of 
inhibition and   93.73 % efficacy. 
The zone of inhibition observed for selected micro-
organism is shown in Figure 7. 
Results obtained from antibacterial activity of F5 
formulation resembles to release profile of drug which 
indicate the dependency of the antibacterial activity with 
the drug release from formulation. 
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Figure 7: Zone of Inhibition of Prepared Formulations 
 
Test for sterility 
There was no a  earance of turbidity and hence no 
e idence of bacterial growth when o timized 
formulation was incubated for    days at   -    c in case 
of fluid thioglycolate medium and at   -     in case of 
soyabean-casein digest medium. The preparations 
examined, therefore, passed the sterility test. 
Isotonicity Evaluation 
The shape of blood cells, blood cells with Besifloxacin 
Hydrochloride F5 and blood cells with Besivance as 
marketed formulation are shown in figure 8. 
Isotonicity testing of Optimized formulation (F5) 
exhibited no change in the shape of blood cells. The 
blood cell size was found in 6-7µm range which reveals 
the isotonic nature of the formulation as compare with 
standard ophthalmic marketed preparation; this indicates 
the maintenance of tonicity in prepared formulations.
 
    
                           a                                              b                                             c         
Figure 8: Shape of Blood Cells 
a, b and c are the image of blood cells, blood cells with besifloxacin hydrochloride in situ ophthalmic gel, blood cells with marketed 
formulation  
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HET-CAM Test 
The results of ocular study indicate that the formulation F5 was non irritant and no ocular damage or abnormal clinical 
signs were visible. 
The ocular irritation study on Chorioallantoic membrane of Hen’s Egg’s shown in Figure 9. 
 
a                                        b                                          c 
 
d                                        e                                              f 
Fig. 9: The ocular irritation study on Chorioallantoic membrane of Hen’s Egg’s. 
A, b, c, d, e, f are images of the ocular irritation study on Chorioallontoic membrane of Hen’s Egg at the time of instillation, after 
1min, 2 min, 3 min, 4 min, 5 min respectively. 
 
Stability study 
Stability study of optimized F5 formulation at room 
temperature was shown in Table 6. Formulations at 
room temperature were found to be stable upto3 months. 
There is no change in drug content, pH, clarity.
 
Table 6: Stability Study Data for F5 Batch 
S. N. Observation Before Stability 
Testing 
During Study 
30 Days 60 Days 90 Days 
1 Clarity Clear Clear Clear Clear 
2 Visual appearance Transparent Transparent Transparent Transparent 
3 pH 6.8 6.8 6.8 6.82 
4 Drug Content 99.1% 99% 99% 98.97% 
 
 
 
 
 
 
 
Waghulde et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2018; 8(5):313-321           
ISSN: 2250-1177                                                                             [321]                                                                             CODEN (USA): JDDTAO 
REFERENCES 
1. Sharma Jitendra PK, Banik A, Dixit S. A New Trend: Ocular 
Drug Delivery System, Pharma Sci Monit: Int J Pharm, 2011; 
2(3):1-25. 
2. Geeta MP, Madhubhai MP. Recent Advances and Challenges 
in Ocular Drug Delivery Systems, Pharma Times, 2007; 
39(1):21-25. 
3. Malik APH, Satyananda S. pH-induced in situ gelling system 
of an anti-infective drug for sustained ocular delivery, J appl 
pharma sci, 4(1):101-104. 
4. Tinu T S, Litha T, Kumar AB. Polymers Used in Ophthalmic 
in Situ Gelling System, Int J Pharm Sci Rev Res, 2013; 
20(1):176-183. 
5. Gambhire S, Bhalerao K, Singh S. In situ Hydrogel: Different 
Approaches to Ocular Drug Delivery, Int J Pharm Sci, 2013; 
5(2):27-36. 
6. Chand S, Sharma A. pH Sensitive in Situ Ocular Gel: A 
Review, J pharm sci bio-sci res, 2016; 6(5):411-417. 
7. Shinkar DM, Dhake AS, Setty CM. Drug Delivery From the 
Oral Cavity: A Focus on Mucoadhesive Buccal Drug Delivery 
Systems, PDA J Pharm Sci and Tech, 2012; 66:466-500. 
8. Deshmukh PK, Fursule RA. Study of a novel environmental 
responsive ophthalmic drug delivery system, Int J Pharm  Biol 
Sci, 2010; 1(2):1-13. 
9. Askarkara  SS, Ganorkara AV, Guptaa KR. Design of 
Experiment Based Validated Stability  Indicating Method for 
Determination of  Besifloxacin Hydrochloride in Bulk Drug 
and Formulation, Biomed J Sci & Tech Res, 2018; 4(4):1-9. 
10. Ikeagwu IJ, Amadi ES, Iroha IR. Antibiotic sensitivity pattern 
of Staphylococcus aureus in Abakaliki, Nigeria, Pak J Med 
Sci, 2008; 24(2):231-235. 
11. Charde    YM, Sharma PH, Choudhary NG, Avari JG. 
Development and Evaluation of herbal formulation for the 
treatment of Acne, Int J Pharm Sci Res, 2014; 6(6):2250-2260.  
12. Gondkar SB, Kute PR, Saudagar RB. Formulation, 
Development and Evaluation Of Ofloxacin In-Situ 
Ophthalmic Gel, World J Pharm Pharma Sci, 2015; 4(11): 
800-822.  
13. Verma L, Sakir M, Singh N, Mehra R, Mehan S. Development 
of phase change solutions for ophthalmic drug delivery based 
on ion activated and pH induced polymers, Int J Pharm Prof 
Res, 2010; 1(2):127-134 
14. Indian Pharmacopoeia, Government of India, Ministry of 
Health and Family Welfare, Published by the Indian 
Pharmacopoeia Commission, Ghaziabad, 2014:59. 
15. United States Pharmacopoeial Convention. The United States 
Pharmacopoeia, 38
th
 Rev. and The National Formulary, 33
rd 
ed. Twinbrook Parkway, Rockville, MD; 2015:125. 
16. Cristina L, Chiva C, Herda R, Corrisitex. BCOP and HET-
CAM as alternative methods to animal experimentation, Braz 
J Pharm Sci, 2009:44. 
17. Saudagar RB, Ghodke RD. Formulation Development and 
Evaluation of Betamethasone Sodium Phosphate In-Situ 
Ophthalmic Gel, Eur j biomed pharm sci, 2017; 4(10):478-
491. 
18. Lucas TI, Bishara RH, Seevers RH. A Stability Program for 
the Distribution of Drug Products: Pharmaceutical 
Technology, 2004: p.69-73. 
19. Cartensen JT, Rhodes CT. Drug Stability: Principles and 
Practices. Third edition: Informa Healthcare: p.582-590.
 
 
 
